Largest Brain Imaging Study Ever Finds All Psychedelics Work Through the Same Brain Mechanism

One Brain Signature to Rule Them All: Study Finds Psilocybin, LSD, and Ayahuasca Share a Common Neural Pathway

The most comprehensive brain imaging analysis of psychedelic drugs to date has found that five different psychedelics — including psilocybin, LSD, and ayahuasca — produce a strikingly similar signature pattern of brain activity, despite having very different chemistry.

The Study

Published in Nature Medicine on April 6, 2026:

• Combined data from 11 brain-imaging studies
• Included 500+ brain scans of 267 people
• Analyzed psilocybin, LSD, ayahuasca, and two other psychedelics
• Developed a method to combine different scanning modalities

Key Finding

Despite different pharmacology:

All five share a common brain signature that increases crosstalk between brain regions.

What This Means

1. Redefining drug categories — The current pharmacological classification may be wrong; mechanism of action matters more than chemical structure
2. Drug design implications — Future psychedelic therapies may target the common pathway directly
3. Clinical trials context — Dozens of trials are testing psychedelics for depression, anxiety, and addiction
4. Safety profile — Shared mechanism means shared side effects and risks

Researcher Quote

"The most surprising finding is that, despite the discrepancies in the pharmacology, there is a common denominator of how they affect the human brain. This puts a question mark on how we're even categorizing them." — Danilo Bzdok, McGill University